Prevention of Staphylococcus aureus infections among surgical patients: Beyond traditional perioperative prophylaxis

Surgery

Volumn 134, Issue 5 SUPPL., 2003, Pages

  Perl, Trish M ^a,b,c,d  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACITRACIN; CEFALEXIN; CEPHALOSPORIN DERIVATIVE; CHLORHEXIDINE; CIPROFLOXACIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; MINOCYCLINE; NEOMYCIN; POVIDONE IODINE; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIUM CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISINFECTION; DOUBLE BLIND PROCEDURE; DRUG COST; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; NASOPHARYNX; NONHUMAN; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SURGICAL INFECTION; SURGICAL PATIENT;

EID: 0346874079     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(03)00391-X     Document Type: Article

References (59)

1. Hall MJ, Lawrence L. Ambulatory surgery in the United States: advance data from vital and health statistics: national hospital discharge survey. Vol 300. Hyattsville (MD): US Dept of Health and Human Services, National Center for Health Statistics; 1998. DHHS Publication (PHS) 98-1250.
2. Horan TC, Culver DH, Gaynes RP, Jarvis WR, Edwards JR, Reid CR. Nosocomial infections in surgical patients in the United States, January 1986-June 1992: national nosocomial infections surveillance (NNIS) system. Infect Control Hosp Epidemiol 1993;14:73-80.
3. Public health focus: surveillance, prevention, and control of nosocomial infections. MMWRM orb Mortal Wkly Rep 1992;41:783-7.
4. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993;6:428-42.
5. Fraser VJ. Starting to learn about the costs of nosocomial infections in the new millennium: where do we go from here? Infect Control Hosp Epidemiol 2002;23:174-6.
6. Kirkland KB, Briggs JP, Trivette SL, Wilkinson WE, Sexton DJ. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs [see comments]. Infect Control Hosp Epidemiol 1999;20:725-30.
7. Boyce JM, Potter-Bynoe G, Dziobek L. Hospital reimbursement patterns among patients with surgical wound infections following open heart surgery. Infect Control Hosp Epidemiol 1990;11:89-93.
8. Leape LL, Brennan TA, Lawthers AG, Hiatt H. Adverse events and negligence in hospitalized patients. Clin Perform Qual Health Care 1993;1:17-21.
9. Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, et al. The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II. N Engl J Med 1991;324:377-84.
10. Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A. The economic impact of Staphylococcus aureus infection in New York City Hospitals. Emerg Infect Dis 1999;5:1-13.
11. Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SL, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592-8.
12. Perl TM, Golub JE. New approaches to reduce Staphylococcus aureus nosocomial infection rates: treating S aureus nasal carriage. Ann Pharmacother 1998;32:S7-16.
13. Kluytmans J, Van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms and associated risks. Clin Microbiol Rev 1997;10: 505-20.
14. Wenzel RP, Perl TM. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect 1995;30:1-12.
15. Mest DR, Wong DH, Shimoda KJ, Mulligan ME, Wilson SE. Nasal colonization with methicillin-resistant Staphylococcus aureus on admission to the surgical intensive care unit increases the risk of infection. Anesth Analg 1994;78: 644-50.
16. Campbell W, Hendrix E, Schwalbe R, Fattom A, Edelman R. Head-injured patients who are nasal carriers of Staphylococcus aureus are at high risk for Staphylococcus aureus pneumonia, [see comments]. Crit Care Med 1999;27:798-801.
17. Pujol M, Pena C, Pallares R, Ariza J, Ayats J, Dominguez MA, et al. Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. Am J Med 1996;100:509-16.
18. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia: study group. N Engl J Med 2001;344:11-6.
19. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002;346:491-6.
20. Shinefield HR, Ribble JC, Boris M, Eichenwald HF. Bacterial interference: its effect on nursery-acquired infection with Staphylococcus aureus. Am J Dis Child 1963;105: 146-54.
21. Boris M, Sellers TF, Eichenwald HF, Shinefield HR. Bacterial interference: protection of adults against nasal colonization of Staphylococcus aureus infection after colonization with a heterologous S. aureus strain. Am J Dis Child 1964;108:252-61.
22. Strauss WG, Maibach HI, Shinefield HR. Bacterial interference treatment of recurrent furunculosis: 2, demonstration of the relationship of strain to pathogenicity. JAMA 1969;208:861-3.
23. Aly R, Shinefield HR, Strauss WG, Maibach HI. Bacterial adherence to nasal mucosal cells. Infect Immun 1977;17: 546-49.
24. Light IJ, Sutherland JM, Schott JE. Control of a staphylococcal outbreak in a nursery: use of bacterial interference. JAMA 1965;193:75-80.
25. Blair EB, Tull AH. Multiple infections among newborns resulting from colonization with S aureus 502A. Am J Clin Pathol 1969;52:42-9.
26. Drutz DJ, Van Way MH, Schaffner W, Koenig MG. Bacterial interference in the therapy of recurrent staphylococcal infections: multiple abscesses due to the implantation of the 502A strain of Staphylococcus. N Engl J Med 1966;275:1161-5.
27. Houck PW, Nelson JD, Kay JL. Fatal septicemia due to S aureus 502A: report of a case and review of the infectious complications of bacterial interference programs. Am J Dis Child 1972;123:45-8.
28. Zimmerman SW, Ahrens E, Johnson CA, Craig W, Leggett J. O'Brien M, et al. Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections. Am J Kidney Dis 1991;18:225-31.
29. Walsh TJ, Standiford HC, Reboli AC, John JF, Mulligan ME, Ribner BS, et al. Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfame-thoxalole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother 1993;37:1334-42.
30. Gordon J. Clinical significance of methicillin-sensitive and methicillin-resistant Staphylococcus aureus in UK hospitals and the relevance of povidone-iodine in their control. Postgrad Med J 1993;69(suppl):S106-16.
31. Mulligan ME, Murray-Leisure KA, Ribner BS, Standiford HC, John JF, Korvick JA, et al. Methicillin-resistant S aureus: a consensus review of the microbiology, pathogenesis, and the epidemiology with implications for prevention and management. Am J Med 1993;94:313-28.
32. Chow JW, Yn VL. Failure of oral ciprofloxacin in suppressing Staphylococcus aureus carriage in haemodialysis patients. J Antimicrob Chemother 1992;29:88-9.
33. Chow JW, Yu VL. Staphylococcal aureus nasal carriage in hemodialysis patients: its role in infection and approaches to prophylaxis. Arch Intern Med 1989;149:1258-62.
34. McAnally TP, Lewis MR, Brown DR. Effect of rifampin and bacitracin on nasal carriers of Staphylococcus aureus. Antimicrob Agents Chemother 1984;25:422-6.
35. Yu VL, Goetz A, Wagener M, Smith PB, Rihs JD, Hanchett J, et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis: efficacy of antibiotic prophylaxis. N Engl J Med 1986;315:91-6.
36. Henkel T, Finlay J. Emergence of resistance during mupirocin treatment: is it a problem in clinical practice? J Chemother 1999;11:331-7.
37. Doebbeling BN, Breneman DL, Neu HC, Aly R, Yangco BG, Holley HP Jr, et al. Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group. Clin Infect Dis 1993;17:466-74.
38. Reagan DR, Doebbeling BN, Pfaller MA, Sheetz CT, Houston AK, Hollis RJ, et al. Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med 1991;114:101-6.
39. Boelaert JR, Van Landuyt HW, Gordts BZ, De Baere YA, Messer SA, Herwaldt LA. Nasal and cutaneous carriage of Staphylococcus aureus in hemodialysis patients: the effect of nasal mupirocin. Infect Control Hosp Epidemiol 1996; 17:809-11.
40. Boelaert JR. Staphylococcus aureus infection in haemodialysis patients: mupirocin as a topical strategy against nasal carriage: a review. J Chemother 1994;6(suppl):19-24.
41. Boelaert JR, De Baere YA, Geernaert MA, Godard CA, Van Landuyt HW. The use of nasal mupirocin ointment to prevent Staphylococcus aureus bacteraemias in haemodialysis patients: an analysis of cost-effectiveness. J Hosp Infect 1991;19(suppl):41-6.
42. Boelaert JR, Van Landuyt HW, Godard CA, Daneels RF, Schurgers ML, Matthys EG, et al. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemias in haemodialysis patients. Nephrol Dial Transplant 1993;8:235-9.
43. Boelaert JR, De Smedt RA, Da Baere YA, Godard CA, Matthys EG, Schurgers ML, et al. The influence of calcium mupirocin nasal ointment on the incidence of Staphylococcus aureus infections in haemodialysis patients. Nephrol Dial Transplant 1989;4:278-81.
44. Kluytmans JA, Manders MJ, van Bommel E, Verbrugh HA. Elimination of nasal carriage of Staphylococcus aureus in hemodialysis patients. Infect Control Hosp Epidemiol 1996;17:793-7.
45. Herwaldt LA. Reduction of Staphylococcus aureus nasal carriage and infection in dialysis patients. J Hosp Infect 1998;40(suppl):S13-23.
46. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis: Mupirocin Study Group. J Am Soc Nephrol 1996;7:2403-8.
47. Kluytmans JA, Mouton JW, VandenBergh MF, Manders MJ, Maat AP, Wagenvoort JH, et al. Reduction of surgical site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 1996;17:780-5.
48. Cimochowski GE, Harostock MD, Brown R, Bernardi M, Alonzo N, Coyle K. Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics. Ann Thorac Surg 2001;71:1572-9.
49. Gernaat-van der Sluis AJ, Hoogenboom-Verdegaal AM, Edixhoven PJ, Spies-van Rooijen NH. Prophylactic mupirocin could reduce orthopedic wound infections: 1,044 patients treated with mupirocin compared with 1,260 historical controls. Acta Orthop Scand 1998;69:412-4.
50. Perl TM, Cullen JJ, Wenzel RP, Zimmerman MB, Pfaller MA, Sheppard D, et al. Intranasal mupirocin to prevent post-operative Staphylococcus aureus infections. N Engl J Med 2002;346:1871-7.
51. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128-40.
52. Bloom BS, Fendrick AM, Chernew ME, Patel P. Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis patients: a decision analysis. Am J Kidney Dis 1996;27:687-94.
53. VandenBergh MFQ, Kluytmans JA, van Hout BA, Seerden RJ, McDonnel J, Verbrugh HA. Cost-effectiveness of perioperative mupirocin nasal ointment in cardiothoracic surgery. Infect Control Hosp Epidemiol 1996;17: 786-92.
54. Deshpande LM, Fix AM, Pfaller MA, Jones RN. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn Microbiol Infect Dis 2002;42:283-90.
55. Farmer TH, Gilbart J, Elson SW. Biochemical basis of mupirocin resistance in strains of Staphylococcus aureus. J Antimicrob Chemother 1992;30:587-96.
56. Chatfield CA, O'Neill WA, Cooke RPD, McGhee KJ, Issack M, Rahman M, et al. Mupirocin-resistant Staphylococcus aureus in a specialist school population. J Hosp Infect 1994;26:273-8.
57. Rahman M, Noble WC, Cookson B. Transmissible mupirocin resistance in Staphylococcus aureus. Epidemiol Infect 1989;102:261-70.
58. Rahman M, Noble WC, Cookson B. Mupirocin-resistant Staphylococcus aureus. Lancet 1987;2:387-8.
59. Miller MA, Dascal A, Portnoy J, Mendelson J. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 1996;17:811-3.